Holen Sie sich die Stockscreener-App
1.58
6.04%
0.09
Handel nachbörslich:
1.55
-0.03
-1.90%
Schlusskurs vom Vortag:
$1.49
Offen:
$1.46
24-Stunden-Volumen:
562.58K
Relative Volume:
0.28
Marktkapitalisierung:
$23.94M
Einnahmen:
$2.79M
Nettoeinkommen (Verlust:
$9.17M
KGV:
1.1541
EPS:
1.369
Netto-Cashflow:
$-20.77M
1W Leistung:
-0.63%
1M Leistung:
+36.21%
6M Leistung:
-38.28%
1J Leistung:
+20.61%
1-Tages-Spanne:
$1.46
$1.61
1-Wochen-Bereich:
$1.37
$1.72
52-Wochen-Spanne:
$0.995
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.58 | 22.57M | 2.79M | 9.17M | -20.77M | 1.369 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Traws Pharma Inc. (TRAW) Q1 2026 Earnings: Better-than-Expected Losses Highlight Cost Discipline Amid Pre-Revenue PhaseElite Trading Signals - Newser
Traws Pharma Q1 2026 Earnings: Narrower Than Expected Loss Despite No RevenueStock Idea Network - Newser
Traws Extends Runway With Financing as Flu Trial Nears - MyChesCo
Traws Pharma Inc files for offering of up to $3.1 million in common stock - marketscreener.com
Traws Pharma Inc Files For Offering Of Up To $3.1 Million In Common Stock - TradingView
TRAW (NASDAQ: TRAW) expands ATM by $3.13M under Citizens JMP agreement - Stock Titan
TRAW Stock Chart | TRAWS PHARMA INC (NASDAQ:TRAW) - ChartMill
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
TRAW Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Buy on Traws Pharma stock, $8 target By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on Traws Pharma stock, $8 target - Investing.com
Traws Pharma (TRAW) asks shareholders to approve 2M-share plan increase, auditor ratification - Stock Titan
Traws Pharma Company Profile & Introduction - Moomoo
[EFFECT] Traws Pharma, Inc. SEC Filing - Stock Titan
Traws Pharma 1Q Loss/Shr 53c >TRAW - Moomoo
Traws Pharma (TRAW) registers 35.9M resale shares including warrants - Stock Titan
Traws Pharma, Inc. Q1 2026 Financial Results & Quarterly SEC Filing Highlights - Minichart
Perceptive (NASDAQ: TRAW) reports 6.1% stake via 979,815 warrants - Stock Titan
Traws Pharma 1Q Rev $0.00 >TRAW - Moomoo
Traws Pharma Releases Q1 2026 Financial Results - AlphaStreet
Traws Pharma Secures $60M Financing, Advances Tivoxavir Marboxil for Influenza and Hantavirus Programs in Q1 2026 Financial Results - Minichart
Traws Pharma (NASDAQ: TRAW) group holds 6.4% (511,714 shares) - Stock Titan
Once-a-month flu shield and hantavirus drug: Traws secures $10M, up to $60M - Stock Titan
Is Traws Pharma (TRAW) a Possible Value Trap After Q1 2026? EPS - GuruFocus
Traws Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Traws Pharma Highlights Q1 Results and Antiviral Pipeline Progress - TipRanks
Traws Pharma, Inc. 1Q 2026: Revenue $0 EPS $(0.53) — 10-Q Summary - TradingView
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results - The Manila Times
Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Traws Pharma, Inc. Quarterly Earnings Report - Stock Titan
Traws Pharma reports Q1 net loss on higher R&D expenses - TradingView
Traws Pharma (NASDAQ: TRAW) details $60M PIPE and Q1 2026 results - Stock Titan
BRIEF-Traws Pharma Inc Q1 Revenue USD 0 - TradingView
Traws Pharma, Inc.Common Stock (NQ: TRAW - FinancialContent
TradingKey - TradingKey
TRAW Stock Surges As Hantavirus Plans Ignite Trading - timothysykes.com
$Traws Pharma (TRAW.US)$ up up up - Moomoo
Traws Pharma Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
Traws Pharma to advance hantavirus candidates - BioWorld News
TRAW Stock Price and Chart — NASDAQ:TRAW - TradingView
Traws Pharma Soars As Hantavirus Antiviral Plan Sparks Rally - timothysykes.com
Traws Pharma (NASDAQ: TRAW) registers 35.9M resale shares - Stock Titan
Traws Pharma to Advance Potential Hantavirus Treatment Clinical Candidates - Contract Pharma
Traws Pharma advances clinical candidates to treat deadly hantavirus infections. - Pluang
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths - TechStock²
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):